Uncaria tomentosa in the treatment of the herpes labialis: randomized double-blind trial / Uncaria tomentosa no tratamento de herpes labial: estudo duplo-cego randomizado

Introduction: the lesions caused by herpes simplex are common and have symptoms affecting the quality of life of affected people. Objective: this study aims to assess the safety efficacy of cream with Uncaria tomentosa (cat?s claw), for topical treatment of the herpes labialis. Methods: a clinical investigation was undertaken by means of controlled, randomized, double-blinded protocol in humans. According to the regulatory procedures, 74 patients were selected based on inclusion/exclusion criteria previously submitted to the Local Ethical Committee (no 144/02) whenever herpes labialis lesion appeared. Following, those selected through medical evaluation received either the test (Uncaria) or the reference (Acyclovir) drug. Results: fifty-four episodes of herpes labialis lesions ecloded in 31 volunteers. After their clinical assessment, one showed 4 episodes, two had 3 episodes and six had 2 infections. Hence, 27 patients received the reference drug while 27 applied the Uncaria cream four times a day. Overall, there were not significant differences between either responses. Although, the Uncaria group showed lower scores on the first two days of treatment (p < 0,005; t = 0,028), on day 3, it was even to Acyclovir. Conclusion:the assessment of clinical efficacy of either treatment demonstrated that both drugs were safe as no adverse reactions were reported. Futher, there was no difference (p > 0,05) in the overall period infections as well as in the inflammatory process or crost formation. Regarding the severity of inflammatory reaction, the clinical efficacy of Uncaria tomentosa was significantly better than acyclovir. Rather than the being antiviral drug, the Uncaria tomentosa may act as an anti-inflammatory agent and this would possibly represent an advantage of not inducing viral resistance for long use.

Introdução: as lesões causadas por herpes simples são comuns e apresentam sintomatologia que altera a qualidade de vida das pessoas acometidas. Objetivo: este estudo visa avaliar a eficácia da segurança de creme com Uncaria tomentosa (unha-de-gato) para o tratamento tópico de herpes labial. Métodos: a pesquisa clínica foi realizada por meio de protocolo controlado, randomizado e duplo-cego. De acordo com os procedimentos de regulamentação, 74pacientes foram selecionados com base em critérios de inclusão e exclusão previamente submetidos à Comissão de Ética Local (no 144/02), sempre a lesão de herpes labial apareceu. Em seguida, os selecionados através de avaliação médica receberam o produto-teste (Uncaria) ou o de referência (aciclovir).Resultados: cinquenta e quatro episódios de lesões de herpes labial eclodiram em 31 voluntários. Após a avaliação clínica, um apresentou quatro episódios, dois tiveram três episódios e seis tinham duas infecções. Assim, 27 pacientes receberam a droga de referência, enquanto 27 aplicaram o creme Uncaria quatro vezes por dia. Em geral, não houve diferença significativa entre as respostas. Contudo, o grupo de Uncaria apresentou escores inferiores nos dois primeiros dias de tratamento (p < 0,005 t = 0,028), depois do dia 3, foi similar ao aciclovir. Conclusão: a avaliação da eficácia clínica dos tratamentosdemonstraram que ambas as drogas foram seguras, bem como não foram notificadas reações adversas. Além disso, não houve diferença significativa (p 0,05) no período total de infecções, bem como no processo inflamatório ou na formação de crosta. Quanto à gravidade da reação inflamatória, a eficácia clínica da Uncaria tomentosa foi significativamente melhor do que o aciclovir. Em vez de a droga ser antiviral, a Uncaria tomentosa pode atuar como um agente anti-inflamatório e isso, possivelmente, representa uma vantagem de não induzir resistência viral para uso por muito tempo.

From pharmaceutical standardizing to clinical research: 20 years of experience with fifty-millesimal potencies

Background: 20 years ago we began to standardize the procedures of preparation and use of fifty-millesimal dilutions (LM or Q) according to indications in the 6th edition of Hahnemann?s Organon. Aim: to describe the main stages in standardization as well as our teaching and research experience on Organon 6th edition. Results: with the use of standardized LM dilutions we observed a lower incidence of homeopathic aggravation than with our earlier experience with non standardized preparations. Organon.modus, a clinical-pharmaceutical protocol derived from the standardization was adequate for the teaching of homeopathy at Faculty of Medicine of Jundiai (São Paulo), the first Brazilian medical school with a graduate course on homeopathy. A randomized double-blind trial comparing individualized homeopathic medicines prescribed in LM dilutions and fluoxetine showed the former not be inferior to the latter in the treatment of moderate-to-severe depression. Conclusion: protocol Organon.modus showed to be adequate to graduate-level teaching of homeopathy and efficient in a controlled clinical trials, favoring its use as common denominator between the art of healing and medical science.

Randomized Double-blind Clinical Trial on Efficacy of Xuezhikang Capsule on Hyperuricacidemia and its Safety / 中国中医药信息杂志

Objective To assess the efficacy of Xuezhikang capsule on hyperuricacidemia and its safety. Methods The study was designed as a random, double-blind placebo controlled clinical trial. 80 hyperuricacidemia patients were divided randomly into test group and control group (40 in test group and 40 in control group). The course of treatment was 28 days. Results 75 patients finished the trial (38 in test group and 37 in control group). After 28 days of treatment, the differences in reduction of UA, XOD, FINs, Homa-IR, TC, TG, Lp, CRP, ET, ?2-MG and elevation of HDL of the test group were statistic significance. No side effect was found in the trial. Conclusion Xuezhikang capsule has good clinical effect and safety in the treatment of hyperuricacidemia.